LB-102

The Global Burden of Disease Study 2021 estimated approximately 23.2 million people living with schizophrenia worldwide (about 0.3% of the global population) and approximately 1.2 million incident cases in 2021, with an age-standardized incidence rate of 15.4 per 100,000. United States estimates differ by method and population. The National Institute of Mental Health reports a prevalence of schizophrenia and related psychotic disorders between 0.25% and 0.64% across studies that use household-based survey samples, clinical diagnostic interviews, and medical records. The Mental and Substance Use Disorders Prevalence Study, which administered a structured clinical interview to 5,679 participants aged 18 to 65 in households, prisons, homeless shelters, and state psychiatric hospitals between October 2020 and October 2022, estimated past-year prevalence of schizophrenia spectrum disorders (schizophrenia, schizoaffective disorder, and schizophreniform disorder) at 1.2% (approximately 2.5 million adults) and lifetime prevalence at 1.8% (approximately 3.7 million adults). A weighted national claims analysis for 2022 estimated the diagnosed prevalence of schizophrenia at 0.45% (1.10% in Medicare fee-for-service, 1.10% in Medicare Advantage, 0.91% in Medicaid, and 0.07% in commercial insurance) and its incidence at 0.08%. A second claims study reported a prevalence of 2.13% in Medicaid (94,153 of 4,414,153) and 0.134% in the employment-based MarketScan database (21,963 of 16,365,997), with 2019 incidence of 0.19% and 0.07%, respectively. In a sample of 328 records representing 493,006 noninstitutionalized civilian persons with schizophrenia, 87% had Medicaid or Medicare, 15% had private insurance for at least one day during the year, and about 7% were uninsured all year. Schizophrenia is typically diagnosed between the late teens and the early thirties.

In 104 participants who responded to treatment of a first episode, the cumulative first relapse rate five years after initial recovery was 81.9%, and discontinuing antipsychotic therapy increased the risk of an initial relapse by almost five times (hazard ratio 4.89). Across 65 trials with data for 6,493 participants, relapse at one year occurred in 27% of those given antipsychotic drugs and 64% of those given placebo. Across 50 studies, the median proportion meeting recovery criteria was 13.5%; in first-episode psychosis, the pooled rate of remission was 58% (mean follow-up 5.5 years) and the pooled prevalence of recovery was 38% (mean follow-up 7.2 years). Across 135 studies, all-cause mortality in people with schizophrenia was 2.52 times that of control groups. In a cohort of 1,138,853 adults with schizophrenia in United States Medicaid, the all-cause standardized mortality ratio was 3.7, and cardiovascular disease had the highest mortality rate (403.2 per 100,000 person-years). One analysis estimated a weighted average of 14.5 years of potential life lost and a weighted average life expectancy of 64.7 years, and the National Institute of Mental Health reports an estimated average of 28.5 years of potential life lost in the United States. The lifetime risk of suicide is approximately 5%; in a cohort of 668,836 Medicare beneficiaries with schizophrenia, the suicide rate was 74.00 per 100,000 person-years, 4.5 times the rate in the general United States population.

Across 12 studies (11,958 participants), the rate of treatment-resistant schizophrenia was 22.8% among all first-episode cohorts. In one cohort, 13,042 of 29,823 people (43.7%) were rehospitalized during follow-up. The 30-day readmission rate after an initial hospital stay with a principal diagnosis of schizophrenia was 15.7%, and Medicaid index admissions for schizophrenia spectrum and other psychotic disorders had a 30-day readmission rate of 23.7% (39,300 readmissions after 166,100 index admissions). Metabolic syndrome was present in 40.9% of 689 CATIE baseline participants by NCEP criteria, the overall rate in a meta-analysis was 32.5%, and the pooled prevalence of cardiovascular disease in severe mental illness was 9.9% (odds ratio 1.53 against controls). At CATIE baseline, 72.9% of participants reported no employment activity, and 16.9% of United States adults with schizophrenia spectrum disorders were employed, compared with 61.0% of adults without. In time trade-off interviews, 49 participants with stable schizophrenia assigned a mean utility of 0.92 to stable schizophrenia and 0.60 to relapse. In a survey of 200 unpaid caregivers in the United States, care averaged 36.1 hours per week and 79% of caregivers met criteria on the Burden Assessment Scale. The excess economic burden of schizophrenia in the United States in 2019 was estimated at $343.2 billion at a prevalence of 1.19% (3,906,050 people), or $87,856 per person, and at $215.1 billion at a lifetime prevalence of 0.72%. The $343.2 billion comprised excess direct health care costs of $62.3 billion ($15,957 per person), direct non-health care costs of $35.0 billion ($8,956 per person), and indirect costs of $251.9 billion ($64,479 per person; 73.4% of the total), of which caregiving contributed $112.3 billion. In the same analysis, mean total health care costs per patient were $26,904 with commercial insurance, $26,095 with Medicaid, and $34,391 with Medicare. Other claims analyses reported total healthcare costs of $32,920 per patient per year in Medicaid, total annual all-cause costs of $23,662 in Medicare fee-for-service, and a mean cost of $1,806 per patient per month in commercial insurance.

Efficacy results for LB-102 are available from one trial, NOVA-1. This phase 2, randomized, double-blind, placebo-controlled, fixed-dose trial was conducted at 25 inpatient sites in the United States. It randomized 359 adults aged 18 to 55 years with an acute exacerbation of schizophrenia (mean baseline PANSS total score approximately 94) in a 3:3:3:1 ratio to placebo (108 participants) or once-daily oral LB-102 50 mg (107), 75 mg (108), or 100 mg (36) for 28 days of inpatient treatment, with no titration. Formal hypothesis testing, with a Hochberg correction, covered the primary endpoint for the 50 mg and 75 mg doses. The 100 mg arm was exploratory; no formal hypothesis was tested for it, and its data were analyzed with the same methods for descriptive purposes. The least-squares mean change in PANSS total score from baseline to week 4 was -9.3 points with placebo, -14.3 with 50 mg, -14.0 with 75 mg, and -16.1 with 100 mg. The differences from placebo were -5.0 points for 50 mg (95% CI -8.0 to -2.1; P<.001), -4.7 points for 75 mg (95% CI -7.7 to -1.7; P=.002), and -6.8 points for 100 mg (95% CI -11.1 to -2.6; P=.002). The sample size calculation had assumed a difference of 8 points. Two sets of post hoc effect sizes are reported. Hedges g, calculated from the observed change in participants who completed the trial, was 0.61 for 50 mg, 0.41 for 75 mg, and 0.83 for 100 mg. The values based on the mixed model for repeated measures were 0.50, 0.45, and 0.64. Week 4 was completed by 81.6% of participants overall: 94 (87%) with placebo, 91 (85%) with 50 mg, 85 (79%) with 75 mg, and 23 (64%) with 100 mg.

In the results that follow, figures are listed in the order placebo, 50 mg, 75 mg, and 100 mg, and P values were not controlled for multiplicity. The differences from placebo in CGI-S score were -0.33 (P<.001), -0.28 (P=.005), and -0.45 (P=.003) for the three doses, and a CGI-S score of 3 or lower at week 4 was reached by 7.4%, 23.4% (P=.001), 17.6% (P=.02), and 11.1% (P=.35) of participants. On the PANSS Positive Symptoms subscale, the differences from placebo were -1.7, -1.7, and -2.2 points (P=.005, .004, and .01). On the PANSS Negative Symptoms subscale, they were -1.1 points for 50 mg (P=.01), -0.6 for 75 mg (P=.16), and -0.7 for 100 mg (P=.26), and on the Marder Negative Symptoms factor the P values were .08, .50, and .07. In the prespecified responder analysis (a reduction of 20% or more in PANSS total score), response occurred in 18.3%, 31.9%, 32.1%, and 43.5% of participants; the comparison with placebo did not reach statistical significance for 50 mg (odds ratio 1.91; 95% CI 0.98 to 3.74; P=.06) and had P=.02 for 75 mg and for 100 mg. A post hoc analysis that rescaled item scores from a 1 to 7 range to a 0 to 6 range found response in 38.7%, 57.1%, 53.6%, and 78.3%. Cognition results are post hoc Cogstate composite scores in the 290 participants who completed week 4 with valid PANSS and Cogstate scores; the Global Cognition effect size against placebo was 0.26 for 50 mg (P=0.0476), 0.41 for 75 mg (P=0.0027), and 0.66 for 100 mg (P=0.0018). No patient-reported outcome or health-related quality of life result was found.

Any adverse event was reported in 62.0%, 72.0%, 63.0%, and 77.8% of participants, treatment-emergent adverse events in 55.6%, 69.2%, 57.4%, and 75.0%, and treatment-related events in 21.3%, 45.8%, 31.5%, and 47.2%. Serious treatment-emergent events occurred in 2 participants with placebo (psychotic disorder and 1 death) and in 1 participant in each LB-102 arm: suicidal ideation with 50 mg and dystonia with 75 mg, both deemed possibly related to treatment, and psychotic disorder with 100 mg, deemed not related. Adverse events led to withdrawal in 2 (1.9%), 2 (1.9%), 3 (2.8%), and 3 (8.3%) participants. The most frequent events were insomnia (22.2%, 25.2%, 21.3%, and 38.9%), headache (9.3%, 11.2%, 8.3%, and 5.6%), anxiety (8.3%, 9.3%, 8.3%, and 11.1%), agitation (9.3%, 10.3%, 5.6%, and 11.1%), and weight increase (3.7%, 12.1%, 7.4%, and 8.3%). The sources report extrapyramidal events at different levels of aggregation. The publication gives an extrapyramidal symptom incidence of 1.9%, 0%, 0.9%, and 2.8% and a dystonia incidence of 0.9%, 0%, 2.8%, and 2.8%. The Form 10-K and a 2026 congress presentation total dystonia, akathisia, and extrapyramidal disorder as 4 (3.7%), 1 (1.0% in the Form 10-K and 0.9% in the presentation), 6 (5.6%), and 2 (5.6%) participants. Akathisia was reported in 1, 1, 2, and 0 participants. Scores on the Simpson-Angus Scale, the Barnes Akathisia Rating Scale, and the Abnormal Involuntary Movement Scale remained stable over time.

Prolactin is reported three ways. As a laboratory finding, elevated prolactin at day 28 was present in 5.2%, 91.0%, 94.0%, and 87.5% of participants, with mean increases of 1.3, 59.9, 51.4, and 51.2 ng/mL. As adverse event terms in the publication, blood prolactin increase was recorded in 0%, 6.5%, 5.6%, and 8.3% of participants and hyperprolactinemia in 0%, 3.7%, 1.9%, and 8.3%; the Form 10-K reports hyperprolactinemia in 0, 11 (10.3%), 8 (7.4%), and 6 (16.7%) participants. Clinical adverse events related to prolactin increase (galactorrhea, breast enlargement, and erectile dysfunction) occurred in 0, 2 (1.9%), 1 (0.9%), and 2 (5.6%) participants. Mean QTc change from baseline to day 28 was 1.2, 4.9, 4.3, and 5.4 milliseconds, a change of 30 milliseconds or more occurred in 1 (0.9%), 5 (4.7%), 1 (0.9%), and 1 (2.8%) participants, and the company states that no participant met the prespecified stopping criteria. The sources differ on weight. The table of changes from baseline in the publication gives a mean weight change of 2.0, 4.3, 3.3, and 2.9 kg. The discussion of the same publication gives 2.1 kg with placebo and a range from 3.5 kg (75 mg) to 4.6 kg (50 mg), and a 2025 poster gives 2.1, 4.6, 3.5, and 3.7 kg. A weight increase of 7% or more occurred in 10.4%, 25.7%, 18.7%, and 8.8% of participants. Placebo-adjusted weight gain was reported as 2 kg in the topline results announcement and as approximately 1.6 kg in the Form 10-K.

In the phase 1 ascending-dose study (64 healthy adults, 48 of whom received LB-102), 4 cases of moderate acute dystonia occurred; 2 of them, at 100 mg twice daily, halted that cohort. QTcF rose by 20 to 46 milliseconds from pre-dose values in all participants given 200 mg once daily, prolactin reached 100 micrograms per liter or more in 11 participants, and the maximum tolerated dose was identified as 150 mg per day. The clinical study report and the NOVA-1 protocol place the single-dose dystonia case at 200 mg once daily, and the publication abstract places it at 100 mg once daily. In the PET study (16 healthy adults), striatal dopamine receptor occupancy at steady state with 50 mg once daily was within the 60% to 80% range, described as approximately 70% in the Form 10-K and as 75% in a 2021 poster, and was approximately 80% with 100 mg. NOVA-2 and NOVA-3 have reported no results. NOVA-2 is a phase 3, randomized, double-blind, placebo-controlled inpatient trial that started in March 2026. It randomizes participants 1:1:1 to LB-102 50 mg, LB-102 100 mg, or placebo for 6 weeks at approximately 25 sites in the United States, and its primary endpoint is the change in PANSS total score at week 6. Planned enrollment is 456 participants in the registry record and approximately 460 in company statements. The company expects topline results in the first half of 2027, and the registry record lists an estimated primary completion of June 2027. NOVA-3 is a 52-week, open-label safety and tolerability trial of flexible dosing from 50 mg to 100 mg in adults with stable schizophrenia. Its planned enrollment is 900 participants, who include participants completing NOVA-2 and newly enrolled participants, and its estimated primary completion is December 2028.

No price, economic model, cost-effectiveness analysis, budget impact analysis, or health technology assessment of LB-102 has been published, and no published peak sales estimate or market research forecast naming LB-102 was identified. The company has stated no launch date; it expects topline results from the phase 3 NOVA-2 trial in the first half of 2027 and expects to schedule a pre-NDA meeting with the FDA in the second half of 2027. The company sizes the United States branded antipsychotic market at approximately $12 billion, reports that four branded products accounted for approximately 60% of 2025 sales (Vraylar $3.6 billion, Rexulti $1.9 billion, Abilify $1.1 billion, and Caplyta $0.9 billion), and states that antipsychotic development typically starts in schizophrenia “to anchor dose and premium pricing” before expansion to bipolar depression and major depressive disorder. Two analyst firms that initiated coverage in October 2025, Piper Sandler and Stifel, each used the term “blockbuster” for the LB-102 opportunity. The Form 10-K lists price, the level of generic competition, and the availability of reimbursement among the competitive factors for LB-102.

The available cost evidence is disease-level. Estimates of the eligible population depend on method: a weighted national claims analysis for 2022 estimated the diagnosed prevalence of schizophrenia at 0.45% (1.10% in Medicare fee-for-service, 1.10% in Medicare Advantage, 0.91% in Medicaid, and 0.07% in commercial insurance); the 2019 United States economic burden analysis applied a prevalence of 1.19% (3,906,050 people); and the Institute for Clinical and Economic Review (ICER) applied an adult prevalence of 1.8% and an antipsychotic treatment rate of 71.3% to estimate 3,459,146 eligible adults. In the 2019 analysis, excess direct health care costs were $62.3 billion ($15,957 per person), including $30.2 billion for inpatient care and $12.1 billion for pharmacy, and mean total health care costs per patient were $26,904 with commercial insurance, $26,095 with Medicaid, and $34,391 with Medicare. Other claims analyses reported total healthcare costs of $32,920 per patient per year in Medicaid, total annual all-cause costs of $23,662 in Medicare fee-for-service, and a mean cost of $1,806 per patient per month in commercial insurance, compared with $419 per member per month in a demographically adjusted population without schizophrenia. In a Medicaid analysis of 158,763 people with schizophrenia, the 18,771 (11.8%) with a recent relapse had mean total healthcare costs $21,862 higher than their controls ($37,424 compared with $15,563).

Economic evaluations exist for another branded oral treatment for schizophrenia, xanomeline-trospium (Cobenfy, studied as KarXT), and are given here as context. Bristol Myers Squibb executives stated a list price of $1,850 for a month's supply, or $22,500 annually, before insurance and other rebates. ICER evaluated KarXT while its price was unknown, using a placeholder price of $20,000 per year in a lifetime model from the health care sector perspective in which individuals started on KarXT or aripiprazole. The base case estimated $163,000 per quality-adjusted life-year (QALY) gained and $146,000 per equal-value life-year gained, and the health benefit price benchmark was $16,000 to $20,000 per year; the authors identified the assumption that KarXT carries no metabolic risk beyond that of the general population as a key driver of the cost-effectiveness findings. The ICER budget impact analysis assumed that 20% of the 3,459,146 eligible adults would initiate treatment in each of five years and found that approximately 8% of eligible adults could be treated at the placeholder price without crossing the potential budget impact threshold of $735 million per year; ICER issued no access and affordability alert. The appraisal panel voted 10 to 2 that the evidence was inadequate to demonstrate a net health benefit superior to that of aripiprazole, and the published summary stated that limited prior authorization is reasonable for payers, given uncertainty about the long-term effectiveness of KarXT and its presumed high cost relative to generic treatment options. A 2025 conference abstract that used a lifetime Markov model from a United States healthcare perspective estimated $727,796 per QALY gained for xanomeline-trospium compared with aripiprazole. Budget impact for LB-102 therefore cannot be estimated from public data as of October 2026.

LB-102 is an investigational, once-daily, oral small molecule. It is an N-methylated version of amisulpride and a selective antagonist of dopamine D2 and D3 receptors and serotonin 5-HT7 receptors. Its parent compound, amisulpride, is approved for schizophrenia in more than 50 countries outside the United States. The company states that it has no product approved for commercial sale and none for which regulatory approval to market has been sought. No nonproprietary or brand name, expedited program designation, submission date, or launch date was identified. The company expects topline results from the phase 3 NOVA-2 trial in the first half of 2027 and a pre-NDA meeting with the FDA in the second half of 2027. According to the company, the FDA noted in writing that NOVA-1 “appeared to have many of the characteristics of an adequate and well-controlled trial”, and the company plans to use NOVA-1 as one of the two adequate and well-controlled trials required for approval. The Form 10-K adds that the adequacy of NOVA-1 will be reviewed at the time of NDA submission and that an additional pivotal trial may be required. The company anticipates that the FDA will require 1,500 cumulative exposures to LB-102, including at least 300 participants with 6 months or more and at least 100 participants with 1 year or more of exposure, and it expects to enroll approximately 900 participants in the open-label NOVA-3 trial as a result.

The evidence establishes a difference from placebo on the PANSS total score after 4 weeks for the 50 mg and 75 mg doses in one trial of 359 participants at inpatient sites in the United States: -5.0 points (95% CI -8.0 to -2.1) and -4.7 points (95% CI -7.7 to -1.7), against a placebo change of -9.3 points. The 100 mg arm (-6.8 points; 95% CI -11.1 to -2.6) was exploratory, with 36 participants randomized and 23 completing week 4, and NOVA-2 studies 50 mg and 100 mg. NOVA-1 had no active comparator, lasted 4 weeks, excluded first-episode and treatment-resistant illness, and enrolled a population that was 80.8% male and 76.6% Black or African American. No efficacy or safety data beyond 4 weeks, no maintenance or relapse-prevention data, no outpatient efficacy data, and no patient-reported outcome results are available. P values for secondary endpoints were not controlled for multiplicity, the prespecified 20% responder comparison for 50 mg had P=.06, the difference on the PANSS Negative Symptoms subscale had P=.01 for 50 mg and P=.16 and P=.26 for 75 mg and 100 mg, and the cognition results are post hoc composites. The authors state that improvement in negative symptoms in a 4-week acute trial may be secondary to resolution of positive symptoms. NOVA-2 compares LB-102 with placebo for 6 weeks, and NOVA-3 is open-label.

Every comparison of LB-102 with another antipsychotic is indirect and made across trials that differ in duration, baseline severity, and placebo response. The company states that it has conducted no head-to-head clinical trial against amisulpride, and no network meta-analysis or indirect treatment comparison that includes LB-102 was identified. The NOVA-1 effect sizes were 0.61, 0.41, and 0.83 for 50 mg, 75 mg, and 100 mg as post hoc Hedges g in participants who completed the trial and 0.50, 0.45, and 0.64 as model-based values. The NOVA-1 authors place these within the range of a network meta-analysis of oral antipsychotics, from which they cite standardized mean differences of -0.73 for amisulpride, -0.56 for olanzapine, and -0.55 for risperidone; the authors of that meta-analysis note that no placebo-controlled amisulpride study was available, which makes the amisulpride evidence indirect. The company states that dopamine receptor occupancy at 50 mg of LB-102 is approximately equivalent to that at 300 to 400 mg of amisulpride. In trials of other oral agents, the placebo-subtracted difference in PANSS total score was -9.6 and -8.4 points at 5 weeks for xanomeline-trospium (placebo changes of -11.6 and -12.2 points), -5.8 and -4.2 points at 4 weeks for lumateperone 42 mg, and -6.0 to -10.4 points at 6 weeks across three cariprazine trials. A meta-analysis of three 5-week xanomeline-trospium trials gave a standardized mean difference of -0.56 (95% CI -0.72 to -0.40).

Four tolerability findings are relevant to formulary review. Elevated prolactin at day 28 was reported in 87.5% to 94.0% of LB-102 participants and 5.2% of placebo participants, with mean increases of 51.2 to 59.9 ng/mL and 1.3 ng/mL, and 5 LB-102 participants had a prolactin-related clinical adverse event within 4 weeks. In the network meta-analysis, the largest mean difference from placebo in prolactin was 48.51 ng/mL (paliperidone), the NOVA-1 authors cite hyperprolactinemia rates of 25% to 100% for amisulpride, and a 2025 review states that hyperprolactinemia “may limit its usability in the future”. A weight increase of 7% or more occurred in 25.7%, 18.7%, and 8.8% of participants receiving 50 mg, 75 mg, and 100 mg and in 10.4% receiving placebo; the authors cite weight change against placebo of -0.37 kg for xanomeline-trospium and 2.78 kg for olanzapine and state that site smoking restrictions, limited physical activity, and minimal dietary restrictions may have contributed to weight gain in NOVA-1. Mean QTc change was 4.3 to 5.4 milliseconds with LB-102 and 1.2 milliseconds with placebo, within a network meta-analysis range of -2.21 milliseconds (lurasidone) to 23.90 milliseconds (sertindole); in phase 1, QTcF rose by 20 to 46 milliseconds after a single 200 mg dose. Extrapyramidal symptom incidence was 0% to 2.8% with LB-102 and 1.9% with placebo in the publication, and 1.0% to 5.6% and 3.7% in the company total that adds dystonia and akathisia; in healthy adults, acute dystonia occurred at 150 mg to 200 mg per day and halted the 100 mg twice-daily cohort.

Current antipsychotic treatment has documented limitations. In CATIE, 1,061 of 1,432 participants (74%) discontinued the assigned antipsychotic before 18 months. Across 167 placebo-controlled trials, at least a minimal response occurred in 51% of participants receiving an antipsychotic and 30% receiving placebo. Treatment resistance developed in 22.8% of first-episode cohorts, and relapse at 1 year occurred in 27% of participants receiving maintenance antipsychotic treatment and 64% receiving placebo. Up to 60% of people with schizophrenia have prominent negative symptoms, and the company states that no therapy is approved in the United States for predominantly negative symptoms or for cognitive impairment associated with schizophrenia. NOVA-1 excluded treatment-resistant illness and provides no data on long-term discontinuation or relapse. For a formulary decision, the following remain unknown: the price, for which no announcement, economic model, or health technology assessment was identified; the labeled indication, dose, and warnings; efficacy and safety beyond 4 weeks; the results of NOVA-2 and NOVA-3; and effectiveness relative to amisulpride and to generic antipsychotics.